News & Press: Latest News

MDMA Announces New Additions to Board of Directors

Friday, January 24, 2014  
Share |
MDMA Announces New Additions to Board of Directors
AcuFocus, ResMed, Teleflex and Welch Allyn CEOs to build on passionate advocacy
 
WASHINGTON, DC – The Medical Device Manufacturers Association (MDMA) today announced the newest additions to its Board of Directors, bolstering the organization’s leadership and expanding its geographic footprint. The four new members of the board are Jim Mazzo, Chairman & CEO of AcuFocus, Michael Farrell, CEO of ResMed, Benson Smith, Chairman, President & CEO of Teleflex, Inc., and Steve Meyer, President & CEO of Welch Allyn.

"These four industry leaders share the passion and dedication embodied by our members, as well as the commitment that drives the MDMA team,” said Dan Moore, President & CEO of Cyberonics Inc. and MDMA Chairman. "Their diverse experiences will be a tremendous asset for MDMA’s activities in 2014 and beyond.  We look forward to working with them as medical technology innovators confront the challenges facing our dynamic industry, and continue to bring cost effective solutions that will enhance patient care.”
 
Mark Leahey, President and CEO of MDMA, noted how critical it is to protect America’s leadership in such an important high-tech, manufacturing-based industry.
 
"MDMA has a proud tradition of passionate advocacy and engagement on issues impacting medical technology stakeholders, and the newest board members share our vision for what the 21st century can mean for patients and providers,” said Leahey.  "As MDMA continues to grow as an organization and help shape the landscape for medical technology innovation, the collective efforts of our board and our members will strengthen America’s position as the global leader.” 
 
Jim Mazzo’s 35-year career in the healthcare industry includes seven years as Chairman, President and CEO of Advanced Medical Optics (AMO), which was sold to Abbott Labs in 2009 for $2.8 billion. He was previously with AMO’s parent company, Allergan, for over 20 years in a variety of roles. He led the spinoff of AMO from Allergan in 2002, expanding the business into a $1 billion industry-leading, publicly-traded corporation.  Jim currently serves as Chairman and CEO of AcuFocus, which specializes in corneal inlays, as well as the Executive Chair at Neurotech Pharmaceuticals.
 
Michael J. Farrell became chief executive officer of ResMed in March 2013. Mr. Farrell has served as the Company’s president – Americas since May 2011, and has served in various other senior executive positions. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting and biotechnology, as well as in chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company, and BHP Billiton.
 
Benson Smith is the Chairman, President and CEO of Teleflex, positions he has held since January 2011. Prior to that, Mr. Smith worked for C.R. Bard, Inc., for approximately 25 years, where he held various executive and senior level positions, including President and Chief Operating Officer of C.R. Bard from 1994 to 1998.
 
Steve Meyer is chief executive officer and president of Welch Allyn, a privately-held manufacturer of frontline medical equipment and diagnostic solutions headquartered in Skaneateles Falls, New York. Over the last 30 years, Steve has held a series of senior leadership roles at Welch Allyn in a variety of areas from international sales and marketing to product development and general management. Most recently Steve served as chief global business officer. 
 
MDMA is the leading voice representing the interests of innovative and entrepreneurial medical technology companies. MDMA members all share a common goal: to provide patients and clinicians with timely access to safe and effective medical technologies that improve the quality of life. 
 
###